X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Triferic AVNU contains iron in the form of ferric pyrophosphate citrate. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin. It is indicated as an iron replacement product indicated for adult patients with HDD-CKD.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Nephrology Product Name: Triferic AVNU
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rockwell Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Company received feedback from USFDA regarding IND of Triferic (Ferric Pyrophosphate Citrate), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Hematology Product Name: Triferic
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
TRIFERIC is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, Safety profile of drug is similar to placebo in controlled clinical trials in patients with end-stage kidney disease.
Lead Product(s): Ferric Pyrophosphate Citrate,Heparin Sodium
Therapeutic Area: Nephrology Product Name: Triferic
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
Rockwell Medical is advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Hematology Product Name: Triferic
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Hematology Product Name: Triferic
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Under the terms of the license agreement, Drogsan will be the exclusive development and commercialization partner for Triferic (ferric pyrophosphate citrate injection) in Turkey and Rockwell Medical will supply the product to Drogsan.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Hematology Product Name: Triferic AVNU
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Drogsan Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 08, 2021
Details:
Under the terms of the agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma.
Lead Product(s): Ferric Pyrophosphate Citrate
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
